ArticleScientific reports2026
Non-albumin proteinuria is associated with all-cause mortality in community-dwelling adults.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Non-albumin proteinuria (NAP), the presence of proteins other than albumin in urine, involves a wide range of urinary proteins that reflect mainly tubular injury. Although hospital-based studies have reported an association between NAP and mortality risk, little is known about this association in community-dwelling adults. This community-based prospective cohort study conducted in Japan included 6,601 participants (aged ≥ 40 years, 48.0% women). We assessed NAP as the difference between the urine albumin-to-creatinine ratio (ACR) and the urine protein-to-creatinine ratio. The association of NAP with all-cause mortality was assessed by multivariable Cox proportional hazard regression analysis, with adjustment for potential confounders. During the median follow-up of 11.2 years, a total of 1,182 deaths were documented. For a doubling of NAP, the adjusted hazard ratio (95% confidence interval) for mortality was 1.16 (1.11, 1.21). When further adjusted for ACR levels, this association remained significant (adjusted hazard ratio [95% confidence interval], 1.12 [1.06, 1.18]). We found that higher NAP was positively associated with all-cause mortality independent of albuminuria levels in community-dwelling adults. These findings suggest that NAP may serve as a complementary marker to albuminuria and is associated with elevated mortality risk in community settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.